TWI421250B - 衍生物及其用於治療神經性疾病之用途 - Google Patents

衍生物及其用於治療神經性疾病之用途 Download PDF

Info

Publication number
TWI421250B
TWI421250B TW100124812A TW100124812A TWI421250B TW I421250 B TWI421250 B TW I421250B TW 100124812 A TW100124812 A TW 100124812A TW 100124812 A TW100124812 A TW 100124812A TW I421250 B TWI421250 B TW I421250B
Authority
TW
Taiwan
Prior art keywords
amino
dihydro
alkoxy
alkyl
alkylthio
Prior art date
Application number
TW100124812A
Other languages
English (en)
Chinese (zh)
Other versions
TW201211038A (en
Inventor
Sangamesh Badiger
Murali Chebrolu
Mathias Frederiksen
Philipp Holzer
Konstanze Hurth
Rainer Martin Lueoend
Rainer Machauer
Henrik Moebitz
Ulf Neumann
Rita Ramos
Heinrich Rueeger
Michael Schaefer
Marina Tintelnot-Blomley
Siem Jacob Veenstra
Markus Voegtle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45468934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI421250(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW201211038A publication Critical patent/TW201211038A/zh
Application granted granted Critical
Publication of TWI421250B publication Critical patent/TWI421250B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
TW100124812A 2010-07-13 2011-07-13 衍生物及其用於治療神經性疾病之用途 TWI421250B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36370210P 2010-07-13 2010-07-13
US201161432058P 2011-01-12 2011-01-12
US201161435088P 2011-01-21 2011-01-21

Publications (2)

Publication Number Publication Date
TW201211038A TW201211038A (en) 2012-03-16
TWI421250B true TWI421250B (zh) 2014-01-01

Family

ID=45468934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100124812A TWI421250B (zh) 2010-07-13 2011-07-13 衍生物及其用於治療神經性疾病之用途

Country Status (31)

Country Link
US (2) US20120302558A1 (enExample)
EP (1) EP2483255B1 (enExample)
JP (1) JP5128019B1 (enExample)
KR (2) KR101391041B1 (enExample)
CN (1) CN102666507B (enExample)
AU (1) AU2011278825B2 (enExample)
BR (1) BR112012004154A2 (enExample)
CA (1) CA2771928C (enExample)
CO (1) CO6501189A2 (enExample)
DK (1) DK2483255T3 (enExample)
EA (1) EA020008B1 (enExample)
EC (1) ECSP12011692A (enExample)
ES (1) ES2442905T3 (enExample)
HR (1) HRP20140011T1 (enExample)
IL (1) IL218034A0 (enExample)
IN (1) IN2012DN01269A (enExample)
MA (1) MA33509B1 (enExample)
MX (1) MX2012002439A (enExample)
MY (1) MY150939A (enExample)
NZ (1) NZ598137A (enExample)
PE (1) PE20121617A1 (enExample)
PH (1) PH12012500361A1 (enExample)
PL (1) PL2483255T3 (enExample)
PT (1) PT2483255E (enExample)
RS (1) RS53096B (enExample)
SG (1) SG178311A1 (enExample)
SI (1) SI2483255T1 (enExample)
TN (1) TN2012000067A1 (enExample)
TW (1) TWI421250B (enExample)
WO (1) WO2012006953A1 (enExample)
ZA (1) ZA201200880B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
WO2010036865A2 (en) 2008-09-26 2010-04-01 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
US10028753B2 (en) 2008-09-26 2018-07-24 Relievant Medsystems, Inc. Spine treatment kits
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
SI2411395T1 (sl) 2009-03-23 2013-07-31 Glenmark Pharmaceuticals S.A. Furopirimidindionski derivati kot TRPA1 modulatorji
EA023857B1 (ru) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
CN103261199A (zh) 2010-10-29 2013-08-21 盐野义制药株式会社 萘啶衍生物
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8524897B2 (en) * 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
AU2012206555A1 (en) * 2011-01-12 2013-08-01 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
BR112013017988A2 (pt) * 2011-01-13 2019-09-24 Novartis Ag inibidores de bace-2 para o tratamento de distúrbios metabólicos
PH12013501480A1 (en) 2011-01-13 2022-10-26 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
AU2012243329B2 (en) 2011-04-13 2015-09-17 Merck Sharp & Dohme Corp. 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
JPWO2012147763A1 (ja) 2011-04-26 2014-07-28 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2013028670A1 (en) 2011-08-22 2013-02-28 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
WO2014099794A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors
US9489376B2 (en) * 2013-01-02 2016-11-08 International Business Machines Corporation Identifying confidential data in a data item by comparing the data item to similar data items from alternative sources
CN105061305A (zh) * 2015-08-31 2015-11-18 河南师范大学 一步合成3-甲基-2-吡啶甲酸甲酯的方法
CN107723290A (zh) * 2017-08-14 2018-02-23 蔡祥胜 一种重组人卵细胞透明带zp3蛋白及其制备方法
CN112250580A (zh) * 2020-10-28 2021-01-22 上海昂卓新材料科技有限公司 一种2-硝基-2-取代苯基丙烷-1,3-二醇的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687827A (zh) * 2007-04-24 2010-03-31 盐野义制药株式会社 环状基团取代的氨基二氢噻嗪衍生物
US20100160290A1 (en) * 2007-04-24 2010-06-24 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
TW201111373A (en) * 2009-08-19 2011-04-01 Hoffmann La Roche 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20060105872A (ko) 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
PE20060692A1 (es) * 2004-09-21 2006-07-19 Lilly Co Eli Inhibidores bace
US8173642B2 (en) * 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
UY32799A (es) * 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687827A (zh) * 2007-04-24 2010-03-31 盐野义制药株式会社 环状基团取代的氨基二氢噻嗪衍生物
US20100160290A1 (en) * 2007-04-24 2010-06-24 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
TW201111373A (en) * 2009-08-19 2011-04-01 Hoffmann La Roche 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazine derivatives

Also Published As

Publication number Publication date
CN102666507A (zh) 2012-09-12
MA33509B1 (fr) 2012-08-01
TN2012000067A1 (en) 2013-09-19
PL2483255T3 (pl) 2014-03-31
IL218034A0 (en) 2012-04-30
ES2442905T3 (es) 2014-02-14
US20120302558A1 (en) 2012-11-29
ECSP12011692A (es) 2012-03-30
SG178311A1 (en) 2012-03-29
KR101265451B1 (ko) 2013-05-22
PE20121617A1 (es) 2012-12-14
IN2012DN01269A (enExample) 2015-05-15
AU2011278825B2 (en) 2012-09-20
TW201211038A (en) 2012-03-16
SI2483255T1 (sl) 2014-02-28
HRP20140011T1 (hr) 2014-01-31
CA2771928A1 (en) 2012-01-19
BR112012004154A2 (pt) 2017-05-30
PT2483255E (pt) 2014-01-22
PH12012500361A1 (en) 2012-01-19
WO2012006953A1 (en) 2012-01-19
NZ598137A (en) 2014-06-27
EA201200176A1 (ru) 2012-09-28
RS53096B (sr) 2014-06-30
AU2011278825A1 (en) 2012-03-01
KR20120068839A (ko) 2012-06-27
EP2483255A1 (en) 2012-08-08
DK2483255T3 (da) 2014-01-20
KR20130016195A (ko) 2013-02-14
EP2483255B1 (en) 2013-10-16
JP5128019B1 (ja) 2013-01-23
MY150939A (en) 2014-03-14
EA020008B1 (ru) 2014-07-30
KR101391041B1 (ko) 2014-05-07
CO6501189A2 (es) 2012-08-15
JP2013508314A (ja) 2013-03-07
EP2483255A4 (en) 2013-01-09
CN102666507B (zh) 2014-09-17
CA2771928C (en) 2013-08-06
ZA201200880B (en) 2012-08-29
US20120172359A1 (en) 2012-07-05
MX2012002439A (es) 2012-04-10
HK1168091A1 (en) 2012-12-21

Similar Documents

Publication Publication Date Title
TWI421250B (zh) 衍生物及其用於治療神經性疾病之用途
US8207164B2 (en) Oxazine derivatives and their use in the treatment of neurological disorders
US8338413B1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
EP2663559B1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
EP2766358B1 (en) Novel oxazine derivatives and their use in the treatment of disease
EP2663561B1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
KR20120102795A (ko) 피라진 유도체 및 신경계 장애의 치료에서의 그의 용도
HK1166314B (en) Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees